6:25 PM
 | 
Aug 20, 2007
 |  BC Extra  |  Company News

Enzon sells 25% interest in Peg-Intron royalties

ENZN said it sold a 25% interest in its future royalties from Peg-Intron peginterferon alfa-2b to Drug Royalty (Toronto, Ontario) for...

Read the full 92 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >